第三代猪生物瓣二尖瓣置换:意大利多中心研究
该研究回顾性分析了1998至2011年间11个心脏中心805例使用Mosaic猪生物瓣行二尖瓣置换的患者,平均年龄73.5±7岁,58%为女性。中位随访44个月,孤立择期MVR早期死亡率为3.8%,总体早期死亡率为7.8%。10年总体生存率为57.4%,结构性瓣膜衰败和再手术累积发生率分别为5.8%和4.8%,结论认为该瓣膜早期和长期结果满意。
要点
- 孤立择期MVR早期死亡率为3.8%,总体早期死亡率为7.8%。
- 10年总体生存率为57.4%,心源性和瓣膜相关死亡累积率分别为7.4%和1.1%。
- 10年结构性瓣膜衰败和再手术累积发生率分别为5.8%和4.8%。
核心结论
- Mosaic猪生物瓣用于二尖瓣置换在长达14年的随访中提供了满意的早期和长期结果。
研究设计与样本
- 回顾性多中心研究,纳入1998至2011年间11个心脏中心805例使用Mosaic猪生物瓣行二尖瓣置换的患者。
- 患者平均年龄73.5±7岁,女性465例(58%),合并冠状动脉旁路移植术201例(24.9%),主动脉瓣置换152例(18.9%),三尖瓣成形187例(22.3%),其他心脏手术116例(14.4%)。
主要发现
- 孤立择期MVR早期死亡率为3.8%(12/313),总体早期死亡率为7.8%(n=63)。
- 晚期死亡率为3.4%/患者年(95例晚期死亡)。
- 10年总体生存率为57.4%(95%CI 48.8%至67.5%),心源性和瓣膜相关死亡累积率分别为7.4%(95%CI 4.8%至10.1%)和1.1%(95%CI 0.2%至1.9%)。
- 10年血栓栓塞和出血事件累积率分别为6.6%(95%CI 1.4%至11.8%)和3.9%(95%CI 0.1%至8%),人工瓣膜心内膜炎累积发生率为3%(95%CI 1.2%至4.9%),结构性瓣膜衰败和再手术累积发生率分别为5.8%(95%CI 0.2%至11.5%)和4.8%(95%CI 0.7%至10.3%)。
临床怎么用
- 对于需行二尖瓣置换的患者,Mosaic猪生物瓣是可选的人工瓣膜之一,其长期耐久性和安全性数据可供临床决策参考。
局限性
- 本研究为回顾性研究,可能存在选择偏倚和随访不完整等局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative outcomes of a third-generation porcine bioprosthesis for mitral valve replacement (MVR) have been poorly addressed. The objective of this study was to perform an independent, retrospective, multicenter study on outcomes of patients undergoing MVR with a Mosaic (Medtronic Inc, Minneapolis, MN) porcine bioprosthesis. METHODS: From 1998 to 2011, 805 patients underwent MVR with a Mosaic porcine valve in 11 cardiac centers. There were 465 female patients (58%), and the overall mean age was 73.5 ± 7 years. Associated procedures included coronary artery bypass grafting (201 patients; 24.9%), aortic valve replacement (152 patients; 18.9%), tricuspid annuloplasty (187 patients; 22.3%), and other cardiac procedures (116 patients; 14.4%). RESULTS: Median follow-up was 44 months (interquartile range, 16 to 63), with a cumulative duration of 2.769 patient-years. Early mortality for isolated elective MVR was 3.8% (12 of 313), and overall early mortality was 7.8% (n = 63). The rate of late mortality was 3.4%/patient-year (95 late deaths). At 10 years, overall survival was 57.4% (95% confidence interval [CI], 48.8% to 67.5%), and cumulative rates of cardiac- and valve-related death were 7.4% (95% CI, 4.8% to 10.1%) and 1.1% (95% CI, 0.2% to 1.9%), respectively. The 10-year cumulative rates of thromboembolic and hemorrhagic events were 6.6% (95% CI, 1.4% to 11.8%) and 3.9% (95% CI, 0.1% to 8%), respectively, and the 10-year cumulative incidence of prosthetic valve endocarditis was 3% (95% CI, 1.2% to 4.9%). Finally, the 10-year cumulative incidences of structural valve degeneration and reoperations were 5.8% (95% CI, 0.2% to 11.5%) and 4.8% (95% CI, 0.7% to 10.3%), respectively. CONCLUSIONS: This independent, multicenter, retrospective study indicated that the Mosaic porcine bioprosthesis for MVR provides satisfactory results in terms of both early and long-term outcomes up to 14 years from its implantation.
引用
- Lorusso R, Miceli A, Gelsomino S, et al. Mitral Valve Replacement With a Third-Generation Porcine Valve: An Italian Multicentered Study. Ann Thorac Surg. 2019. PMID: 31610166. doi:10.1016/j.athoracsur.2019.08.111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。